Uromigos Live 2024 T Cell Directed Therapy Part 2: Existing Data for T Cell Engagers in CRPC

At Uromigos Live 2024, a panel moderated by Brian Rini focused on T cell directed therapy in prostate cancer and featured discussion on topics including cytokine release syndrome and new trials analyzing acapatamab, xaluritamig, and tarlatamab. The panel featured guests Michael Morris, MD, and Karen Autio, MD, of Memorial Sloan Kettering Cancer Center, and Tanya Dorff, MD, of City of Hope.
In the second part of this session, the panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.